Witness Testimony Regarding Intent to Infringe Excluded Because Defendant Refused Such Discovery Based on Privilege

Jan 17, 2023

Reading Time : 2 min

By: Jason Weil, Rachel J. Elsby, Lisa Hladik (Law Clerk)

In this case, plaintiffs alleged that defendant’s generic drug infringed its patent covering a method of treating hair loss. Before trial, plaintiffs filed two motions in limine seeking to exclude (1) evidence of prior litigation and (2) evidence related to defendant’s intent to infringe. The court granted plaintiffs’ first motion in limine to exclude evidence of the prior lawsuits because, inter alia, the evidence was more prejudicial than probative.

In the second motion in limine, plaintiffs moved to exclude defendant’s evidence relating to its executives’ “business understanding” as to whether it was entitled to practice the methods claimed in the asserted patent. Plaintiffs argued that the executives obtained their understanding from legal counsel, and that it should be excluded because defendant refused discovery of the same evidence based on privileged. The defendant responded that its executives’ understanding was based on public information, including the litigation history between the parties, and therefore did not fall within the scope of information it previously withheld as privileged.

To evaluate the arguments, the district court grouped the evidence defendants sought to introduce into three categories: (1) statements that the plaintiffs had “thrown in the towel” after losing three previous lawsuits between the parties, (2) statements by the defendant’s legal department giving it the go-ahead to launch its generic product and (3) statements related to the outcome of the prior litigation. According to the district court, the evidence in each category would only be admissible if it was either the subject of a waiver or not derived from advice of counsel.

As to the first two categories of evidence, the district court found the statements were clearly derived from advice of counsel. In particular, defendant’s understanding that plaintiffs were “throwing in the towel” and that it had the “green light” to practice the claims was not public information, and must have been obtained from counsel. Because defendant refused discovery into advice it received from counsel, it was precluded from presenting testimony from its executives about their “business understanding” of that advice at trial. As to the third category, the district court found the executives’ understanding regarding the outcome of prior litigation was based on public information, and therefore not privileged even if obtained from counsel. But that finding did not save defendant because the district court separately excluded testimony related to prior litigation through plaintiffs’ first motion in limine.

Practice Tip: In cases involving allegations of willful, contributory or induced infringement, defendants face a difficult choice of whether to waive privilege or potentially face trial without exculpatory evidence regarding their scienter. Thus, it is important to develop an early understanding of the evidence that may be relied on to negate allegations of intent and the source of that evidence to make informed decisions related to privilege during discovery. Likewise, patentees should take deliberate steps in discovery to ensure that defendants are forced to choose whether to waive privilege or forego such evidence.

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.